Healthpeak (DOC) Q2 2026 earnings review
Strategic Recaps De-Risk Balance Sheet While Senior Housing Booms
Healthpeak delivered a strong Q2, highlighted by a massive 19.2% Same-Store Adjusted NOI surge in its Janus Living (Senior Housing) portfolio. Total revenue grew 11% YoY to $771.6M, driving an FFO beat and a guidance raise. Crucially, management proved the private market value of its Outpatient Medical portfolio by closing a $1.025B joint venture with Brookfield at an attractive 5.9% cap rate. These proceeds aggressively de-risked the balance sheet, driving leverage down to 4.7x (from 5.4x in Q1). While the Lab segment's NOI remains negative, sequential occupancy gains suggest the long-awaited bottom may finally be here.
🐂 Bull Case
Janus Living is accelerating rapidly, generating 45% YoY revenue growth and 19.2% Same-Store Adjusted NOI growth. This validates Healthpeak's strategy to heavily consolidate the segment before taking it public.
The Brookfield JV generated $1.025B in cash, allowing Healthpeak to immediately retire $1.025B of debt ($650M in senior notes and $375M in commercial paper). Net Debt to Adjusted EBITDAre plummeted from 5.4x to 4.7x, providing massive balance sheet flexibility.
🐻 Bear Case
Despite management calling a bottom in Q1, Lab Same-Store NOI contracted another 3.2% YoY. Positive leasing velocity hasn't yet offset the financial drag of prior tenant failures and capital constraints.
Healthpeak sold a 49% interest in prime Outpatient Medical assets at a 5.9% cap rate to pay down 3.25% senior notes. While great for the balance sheet, this negative arbitrage creates a cash drag that weighs on near-term FFO growth.
⚖️ Verdict: 🟢
Bullish. Management is executing its complex capital recycling playbook flawlessly. The 5.9% cap rate on the Brookfield JV proves public market implied valuations are too low, and the Senior Housing surge provides an excellent growth engine while the Lab segment stabilizes.
Key Themes
Janus Living (Senior Housing) Growth is Accelerating
The Senior Housing portfolio has shifted from a recovery story into a hyper-growth engine. Janus Living reported a 45% YoY surge in revenue ($216M) and a 34% jump in Adjusted EBITDAre ($79M). Crucially, Same-Store Adjusted NOI expanded 19.2%, with margins expanding by 250 basis points. The company aggressively added $1.0B in acquisitions subsequent to the quarter, utilizing $558M of unrestricted cash with zero outstanding debt.
Valuation Arbitrage via Brookfield JV
A massive validation of Healthpeak's intrinsic value occurred in July. Affiliates of Brookfield bought a 49% non-controlling interest in an 86-property Outpatient Medical portfolio for $1.025B, implying a gross valuation of $2.1B, or $380 per square foot. The 5.9% trailing cash cap rate acts as a strong anchor for private market valuations of stabilized medical real estate, significantly tighter than implied REIT trading multiples.
Outpatient Medical Provides Stable Foundation
Stable. The Outpatient Medical segment posted 2.5% Same-Store Adjusted NOI growth, maintaining high occupancy at 90.7% (+20 bps QoQ). Leasing velocity was healthy, with 327,000 sq ft of new leases and 916,000 sq ft of renewals, supported by a post-quarter pipeline of over 1.08M sq ft in signed LOIs and executed leases. The company also initiated a $20M ground-up development pre-leased to Northside Hospital, yielding higher development returns.
Lab Segment Recovery is Lagging the Narrative
While management previously claimed Q1 was the inflection point for life sciences, the financial data contradicts a rapid recovery. Lab Same-Store Adjusted NOI remains deeply negative at -3.2% YoY. While occupancy *did* increase 80 bps sequentially to 78.5% (verifying some demand recovery), the rent roll-downs and prior tenant failures continue to act as a significant drag on cash generation.
Aggressive Deleveraging Strategy Underway
Management executed a reversing trend on its balance sheet. Using the $1.4B in proceeds from Outpatient Medical recaps and loan repayments, Healthpeak retired $650M of 3.25% senior notes and $375M of commercial paper. This caused Net Debt to Adjusted EBITDAre to plummet from 5.4x in Q1 to a highly conservative 4.7x in Q2, entirely shielding the company from near-term macro interest rate volatility.
Implied Second-Half FFO Deceleration
The updated FY26 Diluted FFO as Adjusted guidance midpoint is $1.75. Given H1 2026 FFO as Adjusted was $0.91 ($0.45 in Q1 + $0.46 in Q2), this implies H2 FFO of just $0.84, or $0.42 per quarter. This sequential deceleration is a direct mathematical consequence of the cash drag created by selling assets at 5.9% cap rates to retire debt priced at 3.25%.
Tech and AI Infrastructure Fueling Platform Scale
Management noted in the Brookfield JV announcement that the premium valuation was heavily supported by Healthpeak's deep health system relationships and its ongoing enterprise-wide investments in technology, systems, and innovation (including AI). This tech stack is allowing Healthpeak to manage a massive portfolio efficiently, serving as the connective tissue for its internalized property management platform.
Other KPIs
Reversing. After hovering between 5.2x and 5.4x for the past year, leverage dropped drastically to 4.7x due to massive cash infusions from the Brookfield JV and subsequent debt paydowns. This provides the company with exceptional dry powder.
Stable. Flat YoY compared to Q2 2025. It remains stable despite massive portfolio reshuffling, asset sales, and the spinning out of Janus Living.
Management executed 5.9M shares repurchased at a weighted average of $16.81 in April 2026. The Board replaced the exhausted facility with a brand new $500M authorization, signaling confidence that the stock remains undervalued relative to private market cap rates.
Guidance
Accelerating slightly vs previous guidance. The midpoint was raised by $0.02 to $1.75. However, because H1 2026 delivered $0.91, the guidance mathematically implies a sequential deceleration in H2 to ~$0.42 per quarter, reflecting the dilution of retiring low-cost debt with higher-yield asset sale proceeds.
Accelerating. The midpoint was bumped up 75 basis points (from -1% to +1% previously). This is primarily driven by the massive outperformance in the Senior Housing portfolio (+19.2% in Q2), which is dragging the consolidated average upwards despite the Lab segment's ongoing weakness.
Accelerating. The midpoint was increased by $0.02, mirroring the FFO adjustment, primarily driven by strong core operational performance in Outpatient and Senior Housing.
Key Questions
Lab Segment Disconnect
Occupancy in the Lab segment rose 80 bps sequentially, but Same-Store NOI fell 3.2% YoY. Are the new leases coming in at significantly lower rental rates than the expiring ones, or is this entirely a lag effect from prior vacancies?
Brookfield JV Expansion
The Brookfield transaction established a very attractive 5.9% cap rate for Outpatient Medical. Is there a pipeline to expand this specific JV structure further, and at what threshold would you stop selling to avoid excessive H2 FFO dilution?
Janus Living Capital Deployment
Janus Living closed $1.0B in acquisitions subsequent to Q2 and has zero debt. What is the target leverage profile for Janus Living going forward, and what yields are you underwriting on these new acquisitions?